Blackrock

Munich Re America Corporation offers a range of property and casualty insurance solutions. It is one of the leading reinsurers in the United States. The corporation operates a national/broker clients division and provides automobile, agricultural, ocean marine, surety, general liability and political risk insurance services. Munich Re America Corporation also offers insurance coverage for workers' compensation and professional liability. Its subsidiaries include American Alternative Insurance Corporation and the Princeton Excess and Surplus Lines Insurance Company. In addition, Munich Re America Corporation maintains regional clients and specialty markets divisions. The corporation is a member of Munich Re Group, which operates more than 50 locations throughout the world. Founded in 1880, the group maintains a staff of over 43,000 employees.

Bloomberg is a global leader in business and financial information, delivering accurate news and insights to decision-makers around the world. With a robust array of products, including the Bloomberg Terminal, Bloomberg Law, and other industry-specific services, the company provides comprehensive tools for data, trading, compliance, and beyond. In addition to its extensive information services, Bloomberg Live experiences engage audiences through high-profile events that fuse expert insights with analytical prowess. These events foster dynamic conversations among industry leaders, shaping trends in various sectors, including finance, technology, and sustainability. Generated from the website

Johnston Associates (JAI), founded by venture capitalist Robert F. Johnston in 1968, specializes in providing seed capital to emerging healthcare-related startups, particularly in the pharmaceutical and biotechnology sectors. The firm has a proven track record of nurturing young companies through financial assistance and strategic managerial and technical support, leveraging an extensive network across academia and the medical community for ongoing growth. JAI has invested in a diverse portfolio of companies, ranging from diagnostics to drug delivery and environmental solutions. With a focus on scientific achievement and market potential, the firm applies stringent criteria for investment, typically committing between $300,000 and $3,000,000 per enterprise, and has been instrumental in the launch and development of notable biotech companies over the decades. Generated from the website